生物制剂在儿童结缔组织病相关间质性肺病中的应用研究进展
Research Progress of Biologics and Antifibrosis Therapy in Children with Connective Tissue Disease-Associated Interstitial Lung Disease
DOI: 10.12677/ACM.2023.132322, PDF,   
作者: 龚 玲*, 舒 畅#：重庆医科大学附属儿童医院呼吸科，国家儿童健康与疾病临床医学研究中心，儿童发育疾病研究教育部重点实验室，儿科学重庆市重点实验室，重庆
关键词: 结缔组织病；间质性肺病；生物制剂；儿童；Connective Tissue Disease； Interstitial Lung Disease； Biologics； Children
摘要: 间质性肺病(ILD)可源于多种不同病因，较常见于结缔组织病(CTD)的肺部并发症，这类并发症可统称为结缔组织病相关间质性肺病(CTD-ILD)。在儿童患者中，CTD-ILD早期症状不明显，容易被忽视，可能进展为肺纤维化，从而降低患儿生存质量、影响预后。目前儿童CTD-ILD尚无明确统一的诊疗指南，但多数研究者认为对于激素联合免疫抑制剂治疗效果欠佳或无效的CTD-ILD患儿，生物制剂将是一种安全有效的治疗选择，且可延缓病情进展及肺功能的恶化。本文总结了现有的生物制剂在成人及儿童CTD-ILD的相关研究，为其在儿童CTD-ILD中的进一步应用提供参考依据。
Abstract: Interstitial lung disease (ILD) can be derived from many different etiologies, and is common in the lung complications of connective tissue disease (CTD), which can be collectively referred to as con-nective tissue disease-associated interstitial lung disease (CTD-ILD). In children, the early symp-toms of CTD-ILD are not obvious and easy to be ignored, which may lead to the progression of pul-monary fibrosis, reduce the quality of life of children and affect the prognosis. At present, there are no clear and unified guidelines for the diagnosis and treatment of pediatric CTD-ILD, but most re-searchers believe that biologics will be a safe and effective treatment option for children with poor or ineffective glucocorticoids combined immunosuppressor on CTD-ILD, and can delay the progres-sion of the disease and the deterioration of lung function. In this paper, the relevant studies of ex-isting biologics in adult and children CTD-ILD were summarized, in order to provide reference for their further application in pediatric CTD-ILD.
文章引用：龚玲, 舒畅. 生物制剂在儿童结缔组织病相关间质性肺病中的应用研究进展[J]. 临床医学进展, 2023, 13(2): 2305-2312. https://doi.org/10.12677/ACM.2023.132322

参考文献

[1] 唐晓蕾, 李彩凤, 赵顺英. 儿童结缔组织病相关肺损害[J]. 中国循证儿科杂志, 2016, 11(2): 148-156.
[2] 徐雪峰, 蒋敏, 刘秀云, 等. 儿童免疫相关性疾病临床实用热点问题专家建议系列之二——中国儿童结缔组织疾病相关间质性肺病变诊治专家建议[J]. 中国实用儿科杂志, 2020, 35(3): 174-179. [Google Scholar] [CrossRef] 
[3] Shao, T., Shi, X., Yang, S., et al. (2021) Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion with Heterogeneous Mechanisms and Treatment Considerations. Fron-tiers in Immunology, 12, Article ID: 684699. [Google Scholar] [CrossRef] [PubMed]
[4] Lafyatis, R., O’Hara, C., Feghali-Bostwick, C.A., et al. (2007) B Cell Infiltration in Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis and Rheumatism, 56, 3167-3168. [Google Scholar] [CrossRef] [PubMed]
[5] Nakazawa, M., Suzuki, K., Takeshita, M., et al. (2021) Distinct Expression of Coinhibitory Molecules on Alveolar T Cells in Patients with Rheumatoid Arthritis-Associated and Idiopathic Inflam-matory Myopathy-Associated Interstitial Lung Disease. Arthritis & Rheumatology (Hoboken, NJ), 73, 576-586. [Google Scholar] [CrossRef] [PubMed]
[6] Karampitsakos, T., Woolard, T., Bouros, D., et al. (2017) Toll-Like Recep-tors in the Pathogenesis of Pulmonary Fibrosis. European Journal of Pharmacology, 808, 35-43. [Google Scholar] [CrossRef] [PubMed]
[7] Bonella, F. and Costabel, U. (2014) Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease. Seminars in Respiratory and Critical Care Medicine, 35, 181-200. [Google Scholar] [CrossRef] [PubMed]
[8] Newton, C.A., Batra, K., Torrealba, J., et al. (2016) Telo-mere-Related Lung Fibrosis Is Diagnostically Heterogeneous but Uniformly Progressive. The European Respiratory Journal, 48, 1710-1720. [Google Scholar] [CrossRef] [PubMed]
[9] Juge, P.A., Lee, J.S., Ebstein, E., et al. (2018) MUC5B Pro-moter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. The New England Journal of Medicine, 379, 2209-2219. [Google Scholar] [CrossRef] 
[10] Lee, J.S. and Fischer, A. (2016) Current and Emerging Treatment Options for Interstitial Lung Disease in Patients with Rheumatic Disease. Expert Review of Clinical Immunol-ogy, 12, 509-520. [Google Scholar] [CrossRef] 
[11] 中国医师协会风湿免疫科医师分会风湿病相关肺血管/间质病学组, 国家风湿病数据中心. 2018中国结缔组织病相关间质性肺病诊断和治疗专家共识[J]. 中华内科杂志, 2018, 57(8): 558-565. [Google Scholar] [CrossRef] [PubMed]
[12] Salles, G., Barrett, M., Foà, R., et al. (2017) Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Advances in Therapy, 34, 2232-2273. [Google Scholar] [CrossRef] [PubMed]
[13] Vacchi, C., Manfredi, A., Cassone, G., et al. (2021) Efficacy and Safety of Rituximab in the Treatment of Connective Tissue Disease-Related Interstitial Lung Disease. Drugs in Context, 10. [Google Scholar] [CrossRef] [PubMed]
[14] François, A., Chatelus, E., Wachsmann, D., et al. (2013) B Lymphocytes and B-Cell Activating Factor Promote Collagen and Profibrotic Markers Expression by Dermal Fibro-blasts in Systemic Sclerosis. Arthritis Research & Therapy, 15, R168. [Google Scholar] [CrossRef] [PubMed]
[15] Duarte, A.C., Cordeiro, A., Fernandes, B.M., et al. (2019) Rituximab in Connective Tissue Disease-Associated Interstitial Lung Disease. Clinical Rheumatology, 38, 2001-2009. [Google Scholar] [CrossRef] [PubMed]
[16] Fui, A., Ber-gantini, L., Selvi, E., et al. (2020) Rituximab Therapy in Interstitial Lung Disease Associated with Rheumatoid Arthritis. Internal Medicine Journal, 50, 330-336. [Google Scholar] [CrossRef] [PubMed]
[17] Sircar, G., Goswami, R.P., Sircar, D., et al. (2018) Intravenous Cyclophosphamide vs Rituximab for the Treatment of Early Diffuse Scleroderma Lung Disease: Open Label, Randomized, Controlled Trial. Rheumatology (Oxford, England), 57, 2106-2113. [Google Scholar] [CrossRef] [PubMed]
[18] Kearsley-Fleet, L., Sampath, S., McCann, L.J., et al. (2019) Use and Effectiveness of Rituximab in Children and Young People with Juvenile Idiopathic Arthritis in a Cohort Study in the United Kingdom. Rheumatology (Oxford, England), 58, 331-335. [Google Scholar] [CrossRef] [PubMed]
[19] Oddis, C.V., Reed, A.M., Aggarwal, R., et al. (2013) Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis: A Randomized, Place-bo-Phase Trial. Arthritis and Rheumatism, 65, 314-324. [Google Scholar] [CrossRef] [PubMed]
[20] Spencer, C.H., Rouster-Stevens, K., Gewanter, H., et al. (2017) Biologic Therapies for Refractory Juvenile Dermatomyositis: Five Years of Experience of the Childhood Arthritis and Rheuma-tology Research Alliance in North America. Pediatric Rheumatology Online Journal, 15, 50. [Google Scholar] [CrossRef] [PubMed]
[21] Nishi, K., Ogura, M., Tamai, N., et al. (2022) Successful Rituxi-mab Treatment for Severe Rapidly Progressive Interstitial Lung Disease with Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis: A Case Report and Literature Review. Pediatric Rheumatology Online Journal, 20, 60. [Google Scholar] [CrossRef] [PubMed]
[22] Mahmoud, I., Jellouli, M., Boukhris, I., et al. (2017) Efficacy and Safety of Rituximab in the Management of Pediatric Systemic Lupus Erythematosus: A Systematic Review. The Journal of Pediatrics, 187, 213-219.e2. [Google Scholar] [CrossRef] [PubMed]
[23] McAtee, C.L., Lubega, J., Underbrink, K., et al. (2021) Associa-tion of Rituximab Use with Adverse Events in Children, Adolescents, and Young Adults. JAMA Network Open, 4, e2036321. [Google Scholar] [CrossRef] [PubMed]
[24] De Benedetti, F., Brunner, H.I., Ruperto, N., et al. (2012) Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. The New England Journal of Medicine, 367, 2385-2395. [Google Scholar] [CrossRef] 
[25] Yokota, S., Itoh, Y., Morio, T., et al. (2016) To-cilizumab in Systemic Juvenile Idiopathic Arthritis in a Real-World Clinical Setting: Results from 1 Year of Postmarket-ing Surveillance Follow-Up of 417 Patients in Japan. Annals of the Rheumatic Diseases, 75, 1654-1660. [Google Scholar] [CrossRef] [PubMed]
[26] Mallalieu, N.L., Wimalasundera, S., Hsu, J.C., et al. (2019) Intravenous Dosing of Tocilizumab in Patients Younger than Two Years of Age with Systemic Juvenile Idiopathic Ar-thritis: Results from an Open-Label Phase 1 Clinical Trial. Pediatric Rheumatology Online Journal, 17, 57. [Google Scholar] [CrossRef] [PubMed]
[27] Malattia, C., Ruperto, N., Pederzoli, S., et al. (2020) Tocilizumab May Slow Radiographic Progression in Patients with Systemic or Polyarticular-Course Juvenile Idiopathic Arthritis: Post Hoc Radiographic Analysis from Two Randomized Controlled Trials. Arthritis Research & Therapy, 22, 211. [Google Scholar] [CrossRef] [PubMed]
[28] Cabrera, N., Duquesne, A., Desjonquères, M., et al. (2016) To-cilizumab in the Treatment of Mixed Connective Tissue Disease and Overlap Syndrome in Children. RMD Open, 2, e000271. [Google Scholar] [CrossRef] [PubMed]
[29] Sukharomana, M., Udomittipong, K., Ru-angchira-Urai, R., et al. (2022) Nonspecific Interstitial Pneumonia in Refractory Systemic Juvenile Idiopathic Arthritis Responded to Tocilizumab Treatment. Asian Pacific Journal of Allergy and Immunology, 40, 172-176.
[30] Maruyama, Y., Shigemura, T., Kobayashi, N., et al. (2022) Efficacy of Tocilizumab for Interstitial Lung Disease Associated with Polyarticular Juvenile Idiopathic Arthritis. Pediatrics International: Official Journal of the Japan Pediatric Society, 64, e14737. [Google Scholar] [CrossRef] [PubMed]
[31] Maniscalco, V., Marrani, E., Rossi, E., et al. (2021) Too Young to Fail: A Case Report on the Effectiveness of Tocilizumab for Paediatric Systemic Sclerosis-Associated Interstitial Lung Disease. Scandinavian Journal of Rheumatology, 50, 491-492. [Google Scholar] [CrossRef] [PubMed]
[32] 张洲, 王秀丽, 赵成广, 等. 阿达木单抗治疗幼年特发性关节炎的疗效分析[J]. 中国医科大学学报, 2022, 51(8): 756-759.
[33] Brunner, H.I., Nanda, K., Toth, M., et al. (2020) Safety and Effectiveness of Adalimumab in Patients with Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results. Arthritis Care & Research, 72, 1420-1430. [Google Scholar] [CrossRef] [PubMed]
[34] Park, J.K., Yoo, H.G., Ahn, D.S., et al. (2012) Successful Treatment for Conventional Treatment-Resistant Dermatomyositis-Associated Interstitial Lung Disease with Adalimumab. Rheumatology International, 32, 3587-3590. [Google Scholar] [CrossRef] [PubMed]
[35] Wang, C.R. (2017) Successful Treatment of Refractory Juvenile Dermatomyositis with Adalimumab. Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskel-etal Diseases, 23, 174-175. [Google Scholar] [CrossRef] 
[36] Jin, J. and Yu, H. (2022) Use of Adalimumab in a Child with Juvenile Dermatomyositis and Calcinosis. Indian Journal of Pediatrics, 89, 1270. [Google Scholar] [CrossRef] [PubMed]
[37] Schiffenbauer, A., Garg, M., Castro, C., et al. (2018) A Ran-domized, Double-Blind, Placebo-Controlled Trial of Infliximab in Refractory Polymyositis and Dermatomyositis. Semi-nars in Arthritis and Rheumatism, 47, 858-864. [Google Scholar] [CrossRef] [PubMed]
[38] Campanilho-Marques, R., Deakin, C.T., Simou, S., et al. (2020) Retrospective Analysis of Infliximab and Adalimumab Treatment in a Large Cohort of Juvenile Dermatomyositis Patients. Arthritis Research & Therapy, 22, 79. [Google Scholar] [CrossRef] [PubMed]
[39] Liu, D.W., Chen, J.J., Tang, X.M., et al. (2020) Infliximab Therapy and Outcomes in Patients with Polyarticular Juvenile Idiopathic Arthritis: A Single-Center Study in China. World Journal of Pediatrics: WJP, 16, 68-73. [Google Scholar] [CrossRef] [PubMed]
[40] Chen, D., Wang, X.B., Zhou, Y., et al. (2013) Efficacy of In-fliximab in the Treatment for Dermatomyositis with Acute Interstitial Pneumonia: A Study of Fourteen Cases and Litera-ture Review. Rheumatology International, 33, 2455-2458. [Google Scholar] [CrossRef] [PubMed]
[41] Huang, Y., Lin, W., Chen, Z., et al. (2019) Effect of Tumor Ne-crosis Factor Inhibitors on Interstitial Lung Disease in Rheumatoid Arthritis: Angel or Demon? Drug Design, Develop-ment and Therapy, 13, 2111-2125. [Google Scholar] [CrossRef] 
[42] Brunner, H.I., Abud-Mendoza, C., Viola, D.O., et al. (2020) Safety and Efficacy of Intravenous Belimumab in Children with Systemic Lupus Erythematosus: Results from a Randomised, Placebo-Controlled Trial. Annals of the Rheumatic Diseases, 79, 1340-1348. [Google Scholar] [CrossRef] [PubMed]
[43] Guzman, M. and Hui-Yuen, J.S. (2020) Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab. Drug Design, Development and Therapy, 14, 2503-2513. [Google Scholar] [CrossRef] 
[44] 曾萍, 曾华松, 唐雪梅, 等. 贝利尤单抗治疗中国儿童系统性红斑狼疮28周有效性和安全性分析: 一项回顾性多中心真实世界的初步研究[J]. 中国实用儿科杂志, 2021, 36(11): 858-868. [Google Scholar] [CrossRef] 
[45] Mwangi, J., Litteken, C., Gorthi, R., et al. (2021) Belimumab in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease: Case Report and Literature Review. Cure-us, 13, e19218. [Google Scholar] [CrossRef] [PubMed]
[46] Brunner, H.I., Wong, R., Nys, M., et al. (2020) Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis. Paediatric Drugs, 22, 653-672. [Google Scholar] [CrossRef] [PubMed]
[47] Vicente-Rabaneda, E.F., Atienza-Mateo, B., Blanco, R., et al. (2021) Efficacy and Safety of Abatacept in Interstitial Lung Disease of Rheumatoid Arthritis: A Systematic Literature Re-view. Autoimmunity Reviews, 20, Article ID: 102830. [Google Scholar] [CrossRef] [PubMed]
[48] Ruperto, N., Brunner, H.I., Synoverska, O., et al. (2021) Tofa-citinib in Juvenile Idiopathic Arthritis: A Double-Blind, Placebo-Controlled, Withdrawal Phase 3 Randomised Trial. The Lancet (London, England), 398, 1984-1996. [Google Scholar] [CrossRef] 
[49] Yu, Z., Wang, L., Quan, M., et al. (2021) Successful Man-agement with Janus Kinase Inhibitor Tofacitinib in Refractory Juvenile Dermatomyositis: A Pilot Study and Literature Review. Rheumatology (Oxford, England), 60, 1700-1707. [Google Scholar] [CrossRef] [PubMed]
[50] Chen, Z., Wang, X. and Ye, S. (2019) Tofacitinib in Amyopa-thic Dermatomyositis-Associated Interstitial Lung Disease. The New England Journal of Medicine, 381, 291-293. [Google Scholar] [CrossRef] 
[51] Vacchi, C., Manfredi, A., Cassone, G., et al. (2021) Tofacitinib for the Treatment of Severe Interstitial Lung Disease Related to Rheumatoid Arthritis. Case Reports in Medicine, 2021, Arti-cle ID: 6652845. [Google Scholar] [CrossRef] [PubMed]

为你推荐